Loading
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Previous close
$4.46
+$0.05 · +1.13%
After-hours
$4.41
−$0.05 · -1.12%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Day range
Current $4.46
52-week range
Current $4.46
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
37
Expensive
Sentiment
65
Bullish
Risk
56
Elevated Risk
Momentum
52
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Day range
Current $4.46
52-week range
Current $4.46
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 14.2M USD | 10.99M USD | 19.05M USD | 39.85M USD | 589K USD |
| Gross profit | 14.2M USD | 10.99M USD | 19.05M USD | 39.85M USD | 589K USD |
| Research and development | 30.81M USD | 26.85M USD | 17.65M USD | 14.36M USD | 15.17M USD |
| Selling, general, and administrative | 21.98M USD | 18.22M USD | 11.96M USD | 7.27M USD | 8.12M USD |
| Operating expenses | 52.8M USD | 73.07M USD | 29.61M USD | 21.62M USD | 23.29M USD |
| Interest expense | 1.47M USD | — | 1.33M USD | 9K USD | 2K USD |
| Depreciation and amortization | 53K USD | 10K USD | 6K USD | 4K USD | 4K USD |
| Operating income | −38.6M USD | −62.07M USD | −10.56M USD | 18.23M USD | −22.71M USD |
| Net income | −49.59M USD | −57.53M USD | −9.99M USD | 17.89M USD | −56.69M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$12.60
182.51% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 6, 2020 | 1:4 | — | — |
Stock split | Apr 12, 2019 | 1:12 | — | — |
Stock split | May 5, 2017 | 1:10 | — | — |
Stock split | May 23, 2005 | 1:100 | — | — |
Effective Nov 6, 2020
1:4
Effective Apr 12, 2019
1:12
Effective May 5, 2017
1:10
Effective May 23, 2005
1:100
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI8.11M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM8.01M0.01%77.7B USD0.19%$277.57-0.05%
iShares Russell 2000 Growth ETFIWO2.84M0.02%14.04B USD0.24%$353.47-0.53%
Vanguard Extended Market ETFVXF2.36M0.00%95.4B USD0.05%$233.13-0.15%
Vanguard Russell 2000 ETFVTWO1.12M0.01%18B USD0.06%$112.1-0.10%
iShares Micro-Cap ETFIWC959.74K0.07%1.32B USD0.60%$182.79-0.31%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC408.72K0.04%1.04B USD0.20%$85.92+0.21%
Fidelity Enhanced Small Cap ETFFESM376.55K0.01%6.41B USD0.28%$45.25+0.07%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
